Results 81 to 90 of about 5,862,089 (150)

Nicotinonitrile based dual inhibitors of tubulin and topoisomerase II exhibit potent anticancer activity

Scientific Reports
A series of 2,4,6-trisubstituted nicotinonitriles, compounds 10–41, was designed as pyridine bridged analogs of combretastatin A4 and evaluated as dual inhibitors of topoisomerase II and tubulin polymerization.
Eman S. Hassan, Abdalla E. A. Hassan, Shaikha S. Al Neyadi, Yasir S. Raouf, Hanem M. Awad, Zakaria K. M. Abdel-Samii, Amany M. M. Al-Mahmoudy, Reham A I. Abou-Elkhair   +7 more
doaj   +1 more source

Combination of approved chemotherapeutics and natural products for topoisomerase II targeting: efficacy and safety in cancer therapy

Holistic Integrative Oncology
Cancer is characterized by abnormal cell growth and remains a leading global cause of death despite advances in conventional therapies. Limitations such as lack of selectivity, cytotoxic side effects, and multidrug resistance underscore the need for ...
Ali H. El-Far, Ahmed Elfadadny, Rokaia F. Ragab, Rania Hamada, Mohamed Elbadawy, Junjiang Fu   +5 more
doaj   +1 more source

Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements

Haematologica, 1998
BACKGROUND AND OBJECTIVE: In therapy-related myelodysplasia (t-MDS) or acute myeloid leukemia (t-AML) balanced chromosome aberrations to bands 11q23 and 21q22 have been significantly related to previous chemotherapy with DNA topoisomerase II inhibitors ...
MK Andersen, B Johansson, SO Larsen, J Pedersen-Bjergaard   +3 more
doaj  

Localisation of DNA topoisomerase II alpha in mouse erythroleukemia cells

, 1999
The presence of DNA topoisomerase II alpha was investigated in interphase and metaphase mouse erythroleukemia (MEL) Friend-S cells, and in extracted with 25 mM lithium diiodosalicylate buffer (Lis) nuclei using indirect immunofluorescence.
Ivanova, E. C., Donev, Rossen Mintchev, Djondjurov, L. P.   +2 more
core   +1 more source

A multispecies toolkit of <i>TOP2</i> hypercleavage mutants for studying topoisomerase II-mediated DNA damage. [PDF]

Proc Natl Acad Sci U S A
Ontoso D, Mehta M, Shabro A, Dittmar J, Reid RJD, Rothstein R, Nitiss JL, Keeney S.   +7 more
europepmc   +1 more source

IID432, a parasite-selective topoisomerase II inhibitor, achieves rapid single-dose parasite clearance in a murine chronic Chagas model. [PDF]

Proc Natl Acad Sci U S A
Saldivia M, Jumani RS, Thomas B, Baxley GM, Sancheti J, Bullara D, Galarneau JR, Cheung H, Chen YL, DeAsis RS, Patra D, René O, Noeske J, Schenk AD, Deniston C, Thakore S, Luu C, Wartchow C, Koester DC, Francisco AF, Blais J, Jiricek J, Hollingsworth SA, Gable JE, Kelly JM, Hochberg N, Knutson CG, Lakshminarayana SB, Sarko C, Manjunatha UH, Osborne CS, Diagana TT, Rao SPS.   +32 more
europepmc   +1 more source

Complex mechanisms of topoisomerase II poisons revealed by whole-genome analysis. [PDF]

Commun Biol
Cao H, Zhang Y, Yang F, Wang C, Wang G, Wang B, Xia L, Lian J, Diao Y, Kapranov P.   +9 more
europepmc   +1 more source

Prime, trap, and fail: engineering chromatin to potentiate topoisomerase II poisons in prostate cancer. [PDF]

Transl Androl Urol
Kwon WA.
europepmc   +1 more source

Processing of DNA Topoisomerase II-DNA-Protein Crosslinks Associated With Anticancer Drugs. [PDF]

Genes Cells
Sakasai R, Iwabuchi K.
europepmc   +1 more source

Structure-Based Drug Design Targeting Topoisomerase II Alpha: Discovery of Potential Antitumor Xanthone Derivatives. [PDF]

Molecules
Le TTH, Nguyen TNH, Pham MQ, Tran TTT, Dinh TT, Tran THV, Tran VL, Pham QL.   +7 more
europepmc   +1 more source